IPG Photonics (IPGP)
NASDAQInformation TechnologySemiconductorsSnapshot 2026-10-29
$75.70+0.23%
Close 2026-10-29 · 1-day change
NASDAQInformation TechnologySemiconductorsSnapshot 2026-10-29
Research Workspace
Put IPGP beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Information Technology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — EPS around $0.40 next quarter: Comparison needs review.
View ThesisRevenue growth is accelerating — up about 13% over the past year.
View GrowthRanks in the weakest quality tier of its industry — roughly the bottom 45%, softest on free-cash-flow margins.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look high — the market is pricing in about 59% growth a year, above the roughly 14% analysts expect, leaving little room for error.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 55% in its worst 12-month stretch.
View RiskIPGP’s case rests on accelerating earnings supporting its premium valuation, despite decelerating revenue growth. Q2 revenue grew 11% year over year, slower than Q1’s 17%. Q2 non-GAAP EPS beat consensus by 45%, strengthening the earnings case. IPGP trades at 45× P/E versus a 34× peer median. The market prices in more growth than our forecast, leaving that premium to be earned. Our model puts the next-quarter miss probability near 19%. The primary EPS pillar needs review because its comparison is unverified. Peer multiples imply a price about 56% below where it trades; the thesis is on watch.
Trailing returns as of 2026-10-29. IPGP is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 9 analysts currently covering IPGP (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare IPGP with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| IPGP Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 9 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Electronic Manufacturing Services — fair value, gap to price, and forward P/E.
Compare the value case
Put IPGP next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Expand Advanced Solutions via Lumibird Medical acquisition
Q2 beat and Lumibird deal support growth objectives.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Expand Advanced Solutions via Lumibird Medical acquisition
Lumibird Medical acquisition supports growth objectives.
Significant investment in medical lasers aligns with revenue growth objective.
Acquisition enhances growth potential and market position.
Lowered earnings expectations may hinder revenue growth.
Advances: Improve gross profit margins
Earnings beat supports revenue growth objective.
